Cargando…

Invasive Ductal Breast Cancer with Osteoclast-Like Giant Cells: A Case Report Based on the Gene Expression Profile for Changes in Management

We report the case of a 49-year-old woman diagnosed with a rare histotype of early breast cancer (BC), invasive ductal carcinoma with osteoclast-like giant cells (OGCs), from the perspective of gene profile analysis tests. The patient underwent a quadrantectomy of the right breast with removal of 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Irelli, Azzurra, Sirufo, Maria Maddalena, Quaglione, Gina Rosaria, De Pietro, Francesca, Bassino, Enrica Maria, D’Ugo, Carlo, Ginaldi, Lia, De Martinis, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927002/
https://www.ncbi.nlm.nih.gov/pubmed/33672165
http://dx.doi.org/10.3390/jpm11020156
_version_ 1783659591999946752
author Irelli, Azzurra
Sirufo, Maria Maddalena
Quaglione, Gina Rosaria
De Pietro, Francesca
Bassino, Enrica Maria
D’Ugo, Carlo
Ginaldi, Lia
De Martinis, Massimo
author_facet Irelli, Azzurra
Sirufo, Maria Maddalena
Quaglione, Gina Rosaria
De Pietro, Francesca
Bassino, Enrica Maria
D’Ugo, Carlo
Ginaldi, Lia
De Martinis, Massimo
author_sort Irelli, Azzurra
collection PubMed
description We report the case of a 49-year-old woman diagnosed with a rare histotype of early breast cancer (BC), invasive ductal carcinoma with osteoclast-like giant cells (OGCs), from the perspective of gene profile analysis tests. The patient underwent a quadrantectomy of the right breast with removal of 2 cm neoplastic nodule and three ipsilateral sentinel lymph nodes. The Oncotype Dx gave a recurrence score (RS) of 23, and taking into account the patient’s age, an RS of 23 corresponds to a chemotherapy benefit of 6.5%. After a multidisciplinary collegial discussion, and in consideration of the patient’s age, the absence of comorbidity, the premenopausal state, the rare histotype and the Oncotype Dx report, the patient was offered adjuvant chemotherapy treatment followed by hormone therapy. This case may be an example of the utility of integrating gene expression profiling tests into clinical practice in the adjuvant treatment decision of a rare histotype BC. The Oncotype Dx test required to supplement the histological examination made us opt for the proposal of a combined treatment of adjuvant chemotherapy followed by adjuvant hormone therapy. It demonstrates the importance of considering molecular tests and, in particular, the Oncotype Dx, in estimating the risk of disease recovery at 10 years in order to identify patients who benefit from hormone therapy alone versus those who benefit from the addition of chemotherapy, all with a view toward patient-centered oncology. Here, we discuss the possible validity and limitations of the Oncotype Dx in a rare luminal A-like histotype with high infiltrate of stromal/inflammatory cells.
format Online
Article
Text
id pubmed-7927002
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79270022021-03-04 Invasive Ductal Breast Cancer with Osteoclast-Like Giant Cells: A Case Report Based on the Gene Expression Profile for Changes in Management Irelli, Azzurra Sirufo, Maria Maddalena Quaglione, Gina Rosaria De Pietro, Francesca Bassino, Enrica Maria D’Ugo, Carlo Ginaldi, Lia De Martinis, Massimo J Pers Med Case Report We report the case of a 49-year-old woman diagnosed with a rare histotype of early breast cancer (BC), invasive ductal carcinoma with osteoclast-like giant cells (OGCs), from the perspective of gene profile analysis tests. The patient underwent a quadrantectomy of the right breast with removal of 2 cm neoplastic nodule and three ipsilateral sentinel lymph nodes. The Oncotype Dx gave a recurrence score (RS) of 23, and taking into account the patient’s age, an RS of 23 corresponds to a chemotherapy benefit of 6.5%. After a multidisciplinary collegial discussion, and in consideration of the patient’s age, the absence of comorbidity, the premenopausal state, the rare histotype and the Oncotype Dx report, the patient was offered adjuvant chemotherapy treatment followed by hormone therapy. This case may be an example of the utility of integrating gene expression profiling tests into clinical practice in the adjuvant treatment decision of a rare histotype BC. The Oncotype Dx test required to supplement the histological examination made us opt for the proposal of a combined treatment of adjuvant chemotherapy followed by adjuvant hormone therapy. It demonstrates the importance of considering molecular tests and, in particular, the Oncotype Dx, in estimating the risk of disease recovery at 10 years in order to identify patients who benefit from hormone therapy alone versus those who benefit from the addition of chemotherapy, all with a view toward patient-centered oncology. Here, we discuss the possible validity and limitations of the Oncotype Dx in a rare luminal A-like histotype with high infiltrate of stromal/inflammatory cells. MDPI 2021-02-23 /pmc/articles/PMC7927002/ /pubmed/33672165 http://dx.doi.org/10.3390/jpm11020156 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Irelli, Azzurra
Sirufo, Maria Maddalena
Quaglione, Gina Rosaria
De Pietro, Francesca
Bassino, Enrica Maria
D’Ugo, Carlo
Ginaldi, Lia
De Martinis, Massimo
Invasive Ductal Breast Cancer with Osteoclast-Like Giant Cells: A Case Report Based on the Gene Expression Profile for Changes in Management
title Invasive Ductal Breast Cancer with Osteoclast-Like Giant Cells: A Case Report Based on the Gene Expression Profile for Changes in Management
title_full Invasive Ductal Breast Cancer with Osteoclast-Like Giant Cells: A Case Report Based on the Gene Expression Profile for Changes in Management
title_fullStr Invasive Ductal Breast Cancer with Osteoclast-Like Giant Cells: A Case Report Based on the Gene Expression Profile for Changes in Management
title_full_unstemmed Invasive Ductal Breast Cancer with Osteoclast-Like Giant Cells: A Case Report Based on the Gene Expression Profile for Changes in Management
title_short Invasive Ductal Breast Cancer with Osteoclast-Like Giant Cells: A Case Report Based on the Gene Expression Profile for Changes in Management
title_sort invasive ductal breast cancer with osteoclast-like giant cells: a case report based on the gene expression profile for changes in management
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927002/
https://www.ncbi.nlm.nih.gov/pubmed/33672165
http://dx.doi.org/10.3390/jpm11020156
work_keys_str_mv AT irelliazzurra invasiveductalbreastcancerwithosteoclastlikegiantcellsacasereportbasedonthegeneexpressionprofileforchangesinmanagement
AT sirufomariamaddalena invasiveductalbreastcancerwithosteoclastlikegiantcellsacasereportbasedonthegeneexpressionprofileforchangesinmanagement
AT quaglioneginarosaria invasiveductalbreastcancerwithosteoclastlikegiantcellsacasereportbasedonthegeneexpressionprofileforchangesinmanagement
AT depietrofrancesca invasiveductalbreastcancerwithosteoclastlikegiantcellsacasereportbasedonthegeneexpressionprofileforchangesinmanagement
AT bassinoenricamaria invasiveductalbreastcancerwithosteoclastlikegiantcellsacasereportbasedonthegeneexpressionprofileforchangesinmanagement
AT dugocarlo invasiveductalbreastcancerwithosteoclastlikegiantcellsacasereportbasedonthegeneexpressionprofileforchangesinmanagement
AT ginaldilia invasiveductalbreastcancerwithosteoclastlikegiantcellsacasereportbasedonthegeneexpressionprofileforchangesinmanagement
AT demartinismassimo invasiveductalbreastcancerwithosteoclastlikegiantcellsacasereportbasedonthegeneexpressionprofileforchangesinmanagement